Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Active, not recruiting · NCT01141309 · Registry updated 2026-07-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid tumor | Active, not recruiting | Phase 2 | 2026-07-21 | NCT01141309 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 753 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Basking Ridge | United States | 12 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Memorial Sloan Kettering Cancer Center @ Suffolk | Commack | United States | 14 |
| Memorial Sloan Kettering Westchester | Harrison | United States | 204 |